• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Fibrinolysis for pulmonary embolism may prevent hemodynamic collapse [PEITHO trial]

byTomi Jun
April 10, 2014
in Chronic Disease, Emergency, Pulmonology
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

Image: CC/Heilman

1. Fibrinolysis in addition to standard anticoagulation reduced hemodynamic decompensation, but did not affect overall mortality, in patients with intermediate-risk pulmonary embolism.  

2. Fibrinolysis was associated with greater risk of bleeding and stroke. 

Evidence Rating Level: 1 (Excellent) 

Study Rundown: A pulmonary embolism (PE) that causes persistent hypotension is considered a massive PE. Those that do not meet this criterion are considered submassive. At present, fibrinolytic therapy is only indicated for massive PE. This trial investigates whether fibrinolytic therapy is appropriate for cases of submassive PE where there is evidence of right ventricular dysfunction and myocardial injury – what the authors call intermediate-risk pulmonary embolism. Fibrinolysis in this setting has been a controversial subject and this is the largest trial to address this question thus far.

The primary outcome in this trial was a composite of hemodynamic decompensation and death from any cause within 7 days of randomization. The results show that fibrinolysis in addition to standard anticoagulation reduced the primary outcome by about 50%. However, fibrinolysis primarily reduced the incidence of hemodynamic decompensation. There was no difference in overall mortality between the two groups either at 7 or 30 days. Death was an infrequent event in both groups, suggesting that the placebo group strategy of standard anticoagulation followed by fibrinolysis in the event of hemodynamic collapse could be a valid approach to management of these patients. Fibrinolysis was associated with a significant increase in the incidence of major extracranial bleeding and stroke.

RELATED REPORTS

#VisualAbstract: Reduced-Dose Apixaban was Noninferior to Full-Dose for Cancer-Associated Venous Thromboembolism

Discharge rates in American emergency departments unchanged for pulmonary embolism

Click to read the study, published today in NEJM

Click to read the accompanying editorial in the NEJM

Relevant Reading: Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review

In-Depth [randomized controlled trial]: A total of 1006 patients from multiple countries were randomized to standard anticoagulation with heparin plus a one-time bolus of either the fibrinolytic, tenecteplase or a bolus of placebo. These were patients with intermediate-risk PE based on CT and/or echocardiography findings consistent with right ventricular dysfunction, plus evidence of myocardial injury confirmed by increased troponin levels.

The primary composite outcome of hemodynamic deterioration or death within 7 days was significantly lower in the fibrinolysis group (2.6% vs. 5.6%, P=0.02). Death within 7 days was not significantly different between the two groups (1.2% vs. 1.8%, P=0.42). There was a lower incidence of hemodynamic decompensation in the fibrinolysis group (1.6% vs. 5.0%, P=0.002).

There was a significantly higher incidence of bleeding and stroke in the fibrinolysis group in the first 7 days: major extracranial bleeding (6.3% vs. 1.2%, P<0.001); minor bleeding (32.6% vs. 8.6%); major bleeding (11.5% vs. 2.4%); stroke (2.4% vs. 0.2%, P=0.003). There was a similar incidence of serious adverse events within the first 30 days after randomization (10.9% vs. 11.8%, P=0.63).

More from this author: Early risk factor for progression of cystic fibrosis identified, Gut microbes implicated in stroke and heart attacks: new dietary link, New leukemia mutation offers therapeutic targets, Childhood ADHD associated with increased risk of suicide, A marker of aggressive liver cancer and potential therapeutic target identified 

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: fibrinolysispulmonary embolism
Previous Post

Spironolactone not beneficial in heart failure with preserved ejection fraction [TOPCAT trial]

Next Post

Colorectal cancer resection associated with more complications in elderly

RelatedReports

#VisualAbstract: Dapagliflozin Reduced Death and Worsening Heart Failure in Transcatheter Aor-tic-Valve Implantation
StudyGraphics

#VisualAbstract: Reduced-Dose Apixaban was Noninferior to Full-Dose for Cancer-Associated Venous Thromboembolism

April 22, 2025
Quick Take: Hospital volume and outcomes for acute pulmonary embolism
Emergency

Discharge rates in American emergency departments unchanged for pulmonary embolism

February 14, 2024
Cardiology

Testosterone-replacement therapy noninferior to placebo for preventing cardiovascular events

July 21, 2023
Nonleg venous thromboses associated with PE, longer ICU stay
Emergency

Indefinite anticoagulation for unprovoked venous thromboembolism is not cost-effective

July 18, 2023
Next Post

Colorectal cancer resection associated with more complications in elderly

Cetuximab and neoadjuvant chemotherapy may decrease survival in liver metastasis

Exemestane for breast cancer prevention has little effect on quality of life

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Long-term use of mometasone (Asmanex) in adults with sickle cell disease without formal diagnosis of asthma may worsen disease activity
  • Few patients had ED lumbar CT or MRI within 30 days after low-acuity back-pain radiography at urgent care centers
  • A 34-circular RNA blood signature predicted Alzheimer’s disease progression and improved prediction when combined with pTau217
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.